Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 12/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 9/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.35 |
| ▸ | KHK | P50053 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30666086 | 1.00 | CYP11B2 (0.41) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL30666087 | 1.00 | CYP11B2 (0.41) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL32674001 | 0.77 | CYP11B2 (0.38) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL480131 | 0.77 | CYP11B2 (0.39) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL29311545 | 0.77 | CYP11B2 (0.42) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL31416799 | 0.77 | CYP11B2 (0.42) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL15057867 | 0.77 | KHK (0.40) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL18121299 | 0.77 | KHK (0.48) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL30673253 | 0.77 | ALDH1A1 (0.44) | CYP11B2TRPV4CYP11B1MEN1KMT2A | |
| SCHEMBL14932505 | 0.77 | TDP1 (0.47) | CYP11B2TRPV4CYP11B1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117199519-A | Electrolyte, preparation method and application thereof, and lithium battery | 北京纳米能源与系统研究所 | 2023-12-08 | — | — | CN | claimed |
| CN-120674589-A | Composition for electrolyte, preparation method and application of electrolyte | 国网湖南省电力有限公司 | 2025-09-19 | — | — | CN | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117199519-A | Electrolyte, preparation method and application thereof, and lithium battery | 北京纳米能源与系统研究所 | 2023-12-08 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3833661-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Valo Early Discovery, Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| CN-112867712-A | Carboxamides as ubiquitin-specific protease inhibitors | 瓦洛早期发现股份有限公司 | 2021-05-28 | — | — | CN | disclosed |
| EP-3665169-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020033707-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2020-02-13 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032863-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | US | disclosed |
| EP-1751119-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | AstraZeneca AB (SE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111001-A1 | NOVEL FUSED HETEROCYCLES AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-11-24 | — | — | WO | disclosed |
| US-4999432-A | Heating and dechlorination of a chloropyridine | DOWELANCO (US) | 1991-03-12 | — | — | US | disclosed |
| EP-0415498-A2 | Fluorination with hydrogen fluoride | DOWELANCO (US) | 1991-03-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CYP11B2 4572/4885TRPV4 4662/4885CYP11B1 4638/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | CYP11B2 4572/4885TRPV4 4662/4885CYP11B1 4638/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | CYP11B2 4572/4885TRPV4 4662/4885CYP11B1 4638/4885 |
| US-20070275954-A1 | Novel Fused Heterocycles and Uses Thereof | VIP, CCKBR, HRH2 | CYP11B2 65/4885TRPV4 4554/4885CYP11B1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.